Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | 류성언 | - |
dc.date.accessioned | 2019-02-12T01:20:48Z | - |
dc.date.available | 2019-02-12T01:20:48Z | - |
dc.date.issued | 2016-10 | - |
dc.identifier.citation | NATURE COMMUNICATIONS, v. 7, Page. 1-10 | en_US |
dc.identifier.issn | 2041-1723 | - |
dc.identifier.uri | https://www.nature.com/articles/ncomms13354 | - |
dc.identifier.uri | https://repository.hanyang.ac.kr/handle/20.500.11754/98833 | - |
dc.description.abstract | Cancer cells express tumour-specific antigens derived via genetic and epigenetic alterations, which may be targeted by T-cell-mediated immune responses. However, cancer cells can avoid immune surveillance by suppressing immunity through activation of specific inhibitory signalling pathways, referred to as immune checkpoints. In recent years, the blockade of checkpoint molecules such as PD-1, PD-L1 and CTLA-4, with monoclonal antibodies has enabled the development of breakthrough therapies in oncology, and four therapeutic antibodies targeting these checkpoint molecules have been approved by the FDA for the treatment of several types of cancer. Here, we report the crystal structures of checkpoint molecules in complex with the Fab fragments of therapeutic antibodies, including PD-1/pembrolizumab, PD-1/nivolumab, PD-L1/BMS-936559 and CTLA-4/tremelimumab. These complex structures elucidate the precise epitopes of the antibodies and the molecular mechanisms underlying checkpoint blockade, providing useful information for the improvement of monoclonal antibodies capable of attenuating checkpoint signalling for the treatment of cancer. | en_US |
dc.description.sponsorship | We are grateful to the staffs of beamline 7A and 5C at Pohang Accelerator Laboratory for help with the X-ray diffraction experiments. This work was supported by grants from the National Research Foundation of Korea (NRF-2015R1D1A1A01057706, 2011-0030030 and 2015M3A9B5030302) funded by the Ministry of Science, ICT and Future Planning. | en_US |
dc.language.iso | en | en_US |
dc.publisher | NATURE PUBLISHING GROUP | en_US |
dc.subject | T-CELL-ACTIVATION | en_US |
dc.subject | IMMUNE-RESPONSES | en_US |
dc.subject | B7 FAMILY | en_US |
dc.subject | CRYSTAL-STRUCTURE | en_US |
dc.subject | CO-STIMULATION | en_US |
dc.subject | PD-1 BLOCKADE | en_US |
dc.subject | LUNG-CANCER | en_US |
dc.subject | DEATH 1 | en_US |
dc.subject | THERAPY | en_US |
dc.subject | COMPLEX | en_US |
dc.title | Structural basis of checkpoint blockade by monoclonal antibodies in cancer immunotherapy | en_US |
dc.type | Article | en_US |
dc.relation.volume | 7 | - |
dc.identifier.doi | 10.1038/ncomms13354 | - |
dc.relation.page | 1-10 | - |
dc.relation.journal | NATURE COMMUNICATIONS | - |
dc.contributor.googleauthor | Lee, Ju Yeon | - |
dc.contributor.googleauthor | Lee, Hyun Tae | - |
dc.contributor.googleauthor | Shin, Woori | - |
dc.contributor.googleauthor | Chae, Jongseok | - |
dc.contributor.googleauthor | Choi, Jaemo | - |
dc.contributor.googleauthor | Kim, Sung Hyun | - |
dc.contributor.googleauthor | Lim, Heejin | - |
dc.contributor.googleauthor | Heo, Tae Won | - |
dc.contributor.googleauthor | Park, Kyeong Young | - |
dc.contributor.googleauthor | Ryu, Seong Eon | - |
dc.relation.code | 2016003600 | - |
dc.sector.campus | S | - |
dc.sector.daehak | COLLEGE OF ENGINEERING[S] | - |
dc.sector.department | DEPARTMENT OF BIOENGINEERING | - |
dc.identifier.pid | ryuse | - |
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.